According to the Medici announcement, net profit attributable to the owners of the parent company is expected to be 42 million yuan to 63 million yuan, turning a loss into a profit, increasing 54.9 million yuan to 75.9 million yuan, an increase of 425.62% to 588.43%; deducted non-net profit is 35 million yuan to 52.5 million yuan, an increase of 61.73 million yuan to 79.23 million yuan over the previous year. Mainly due to the recovery in global demand for innovative drug research and development, the company's revenue increased by about 40% year on year, capacity utilization increased, cost structure optimized, and comprehensive gross margin increased steadily.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.